[{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Plus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"NU-0129","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Shasqi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"SQL70","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"ST101","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Sapience Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Sapience Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Iopofosine I-131","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Mnk1\/2 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Cancer Institute \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ NIH"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Senti Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"ST316","moa":"Beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"N-803","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Mustang Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Versamune-TARP","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic NKT Cell Therapy","moa":"Mutated p53","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Not Applicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CF33-hNIS-antiPDL1","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Privo Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Kintara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ankyra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokines","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"NextCure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"NC525","moa":"LAIR-1","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"STI-001","moa":"STING","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Kintara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"AVM Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Kovina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV protein","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ZEN003694","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"QSAM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Samarium-153 DOTMP","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"STAT3 protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"AUM LifeTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Antisense Oligonucleotides","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"ST101","moa":"C\/EBP beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Synergys Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"SYN-001","moa":"Vasculogenic Mimicry","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ProLynx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"ARTEMIS T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"F3-8-60","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Modifi Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"MGMT","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"Mesothelin","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Turnstone Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Oncolytic Viral Immunotherapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Lintuzumab-ac225","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Gritstone bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Aprea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Tessa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TT11X","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"T-cell based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ Eureka Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Eureka Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"T cell-based Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Nogapendekin alfa Inbakicept","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"ST316","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Iterion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tegavivint","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Helocyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"CMV-MVA Triplex Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"GIGA-564","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Traverse Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"BlueSphere Bio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"TCR T-cell Therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"2","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Biosplice","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Cirtuvivint","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"14","companyTruncated":"National Cancer Institute \/ National Cancer Institute"}]
Find Clinical Drug Pipeline Developments & Deals by National Cancer Institute
Details :
The collaboration aims for Biosplice to expand its clinical candidate, SM08502 (cirtuvivint), as a standalone treatment and combination therapy in patients with AML and MDS.
Details :
The collaboration will seek to advance a novel TCR T-cell therapy, TCX-201, targeting recurrent respiratory papillomatosis (RRP), a rare orphan disease.
Details :
PRGN-2012 a new molecular entity, a HPV 6/11-specific T-cell response inducer, is an off the shelf OTS AdenoVerse gene therapy vaccine. It is in Phase I/II for recurrent respiratory papillomatosis.
Details :
The fundings will be used for the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC), the most prevalent type of lung cancer in the United States.
Details :
The agreement aims to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564, a fully human monoclonal antibody, distinguishes itself from currently available anti-CTLA-4 drugs.
Details :
The Company intends to use the funds for the development of Bria-OTS™, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.
Details :
The funding will be used for clinical studies of Triplex, a cytomegalovirus (CMV), universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine, being developed by Helocyte and City of Hope.
Details :
The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515, a first-in-class deoxycytidine kinase inhibitor, in solid tumors.
Details :
BC2059 (tegavivint) is a first-in-class small molecule inhibitor of Transducin beta-like protein 1 (TBL1), it is being investigated in patients with c-Myc-overexpressing relapsed or refractory large B-Cell lymphomas.
Details :
The funding will be used to investigate pharmacodynamic biomarkers for ST316, a first-in-class beta-catenin antagonist, and evaluate the impact of ST316 on the tumor microenvironment (TME) in patient-derived cancer models.
Reset All
